FTC, Boehringer Wrangle Over Generics Settlement Docs

Law360, Washington (December 9, 2011, 7:30 PM EST) -- The Federal Trade Commission, on the hunt for documents relating to a patent settlement it is investigating between Boehringer Ingelheim Pharmaceuticals Inc. and Barr Pharmaceuticals Inc. that may have unlawfully delayed generic drugs, told a judge Friday that the documents contained factual material, not just attorneys' mental impressions.

In October 2009 the FTC accused Boehringer in Washington federal court of using a number of tactics to delay its investigation, such as inappropriately redacting documents and failing to conduct a careful and thorough search.

The agency's subpoena,...
To view the full article, register now.

Related

Sections

Case Information

Case Title

FEDERAL TRADE COMMISSION v. BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.


Case Number

1:09-mc-00564

Court

District Of Columbia

Nature of Suit

Other Statutory Actions

Judge

G. Michael Harvey

Date Filed

October 23, 2009

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.